We are a precision oncology company focused on the treatment and prevention of virus-associated cancers. Our lead product candidate is Nana-val, an all-oral combination therapy of our proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 trial for the treatment of multiple subtypes of relapsed/refractory EBV+ lymphoma (NAVAL-1).